Page last updated: 2024-12-10

ozagrel

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ozagrel: RN refers to (E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5282440
CHEMBL ID11662
CHEBI ID134938
CHEBI ID92359
SCHEMBL ID4210
MeSH IDM0105954

Synonyms (74)

Synonym
AC-2080
LS-14195
BRD-K53061490-003-03-0
BRD-K19525698-003-01-1
kct-0809
82571-53-7
PRESTWICK2_000979
PRESTWICK3_000979
BPBIO1_001119
AB00514722
(e)-p-(imidazol-1-ylmethyl)cinnamic acid
ozagrel
ozagrel [inn]
ozagrelum [latin]
2-propenoic acid, 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-, (e)-
BSPBIO_001017
NCGC00025195-02
CHEBI:134938
HMS2089O14
CHEMBL11662 ,
cataclot (tn)
ozagrel (inn)
D08327
3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid
3-(4-imidazol-1-ylmethyl-phenyl)-acrylic acid
(e)-3-(4-imidazol-1-ylmethyl-phenyl)-acrylic acid
bdbm50017896
(e)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid
ozagrelum
l256jb984d ,
unii-l256jb984d
AKOS015889403
S2496
ozagrel [mi]
ozagrel [who-dd]
ozagrel [mart.]
HY-B0428
AB00514722-10
SCHEMBL4210
AB00514722-12
AB00514722-13
DTXSID6048547
Q-100843
pulmoza
3-[4-(1h-imidazol-1-ylmethyl)phenyl]-2e-propenoic acid
SHZKQBHERIJWAO-AATRIKPKSA-N
(e)-3-(4-((1h-imidazol-1-yl)methyl)phenyl)acrylic acid
HMS3649M21
AB00514722_14
AB00514722_15
CHEBI:92359
(2e)-3-[4-(1h-imidazol-1-ylmethyl)phenyl]acrylic acid
mfcd00868231
(2e)-3-{4-[(1h-imidazol-1-yl)methyl]phenyl}prop-2-enoic acid
AS-71327
SBI-0207081.P001
SW197369-5
DB12017
gtpl9866
(e)-3-(4-((1h-imidazol-1-yl)methyl)phenyl)
3-[4-(1-imidazolylmethyl)phenyl]-2-propenoic acid
ozagrel free acid
82571-53-7 (free base)
ozagrel,(s)
SR-01000597793-8
oky046
BCP12147
Q7116436
2-propenoic acid, 3-[4-(1h-imidazol-1-ylmethyl)phenyl]-, (2e)-
EX-A5744
HMS3884N21
CCG-266782
ozagrel, oky-046
(e)-3-[p-(1h-imidazol-1-ylmethyl)phenyl]-2-propenoic acid

Research Excerpts

Overview

Ozagrel was estimated to be a reversible mixed-type inhibitor of diphenolase activity. Ozagrel is a promising drug candidate for preventing acute lung injury.

ExcerptReferenceRelevance
"Ozagrel is an inhibitor of thromboxane synthetase."( Ozagrel for Postoperative Management of Aneurysmal Subarachnoid Hemorrhages.
Bhat, DI; Devi, BI; Narayan, V; Prabhuraj, AR; Shukla, D,
)
2.3
"Ozagrel was estimated to be a reversible mixed-type inhibitor of diphenolase activity with the constants (K (S1), K (S2), K (i1), and K (i2)) determined to be 2.21, 3.89, 0.454, and 0.799 mM, repectively."( In vitro effect of ozagrel on mushroom tyrosinase.
Li, SB; Lv, XY; Nie, HL; Qiu, T; Xue, Y; Zhang, HT; Zhou, LM; Zhu, LM, 2009
)
1.4
"Ozagrel is a promising drug candidate for preventing acute lung injury."( A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs.
Hatamoto, K; Irie, T; Irikura, M; Ishitsuka, Y; Isohama, Y; Iyama, K; Kurita, S; Moriuchi, H; Tokunaga, H, 2009
)
1.32

Actions

ExcerptReferenceRelevance
"Ozagrel could inhibit the action of U46619 in promoting the proliferation and expression of Ki67 in PASMC and inhibit the apoptosis of PASMC."( [Effect of TXA2 inhibitor on the proliferation and apoptosis of hypoxic pulmonary artery smooth muscle cells of porcines].
Ding, YP; He, HW; Lin, L; Shi, HF; Yao, HX, 2011
)
1.09

Treatment

Ozagrel treatment also improved those factors compared with saline, in concert with the fast recovery of local CBF with reactive hyperemia. Treatment with ozagrel (400 mg/day for 2 weeks) reduced coughing in 12 patients.

ExcerptReferenceRelevance
"Ozagrel treatment also improved those factors compared with saline, in concert with the fast recovery of local CBF with reactive hyperemia."( Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia.
Hosomi, N; Kohno, M; Mizushige, K; Ohyama, H; Takahashi, T, 2001
)
1.03
"Treatment of ozagrel (10 and 20 mg/kg, p."( Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia.
Bhatia, P; Singh, N, 2021
)
1.28
"Treatment of ozagrel (10 & 20 mg/kg, p."( Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia.
Bhatia, P; Kaur, G; Singh, N, 2021
)
2.42
"Treatment with ozagrel (400 mg/day for 2 weeks) reduced coughing in 12 patients."( [Effects of a thromboxane-synthetase inhibitor in patients with chronic persistent coughing and no airwayhyperresponsiveness].
Fujimura, M; Matsuda, T; Mizuguchi, M; Nishi, K; Ooka, T; Tachibana, H; Watanabe, K, 1997
)
0.64

Toxicity

ExcerptReferenceRelevance
" However, this drug has a hazardous side effect in that it may promote a tendency to bleed, which caused death in one of our patients."( Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage.
Nii, Y; Ohnishi, T; Tokiyoshi, K, 1991
)
0.28
" The occurrence of adverse events, occurrence of low density areas associated with vasospasm on computed tomography, absence of symptomatic vasospasm, and poor clinical outcomes associated with vasospasm were compared between the fasudil and fasudil plus ozagrel groups."( Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study.
Satoh, S; Seto, M; Shibuya, M; Sugiyama, H; Suzuki, Y; Takakura, K, 2008
)
0.77

Pharmacokinetics

The pharmacokinetic and pharmacodynamic (PK/PD) characteristics of ozagrel, a new potent and selective thromboxane synthetase inhibitor, were investigated.

ExcerptReferenceRelevance
"The pharmacokinetic and pharmacodynamic (PK/PD) characteristics of ozagrel, a new potent and selective thromboxane synthetase inhibitor, were investigated in rabbits after its intravenous, oral, and rectal administration."( Pharmacokinetic and pharmacodynamic studies of a thromboxane synthetase inhibitor, ozagrel, in rabbits.
Adachi, I; Horikoshi, I; Kanamoto, I; Sato, H; Zheng, NX, 1995
)
0.75
" The pharmacokinetic parameters of ozagrel, were as follows: Cmax was 32."( [Pharmacokinetic comparison of two ozagrel polymorph forms in SD rats].
Chen, QX; Du, GH; Lü, Y; Qin, ZZ; Song, JK, 2015
)
0.97

Dosage Studied

ExcerptRelevanceReference
" Tachyphylaxis was not noted in 5 control pigs given sequential repeats of the PAF dosing series."( In vivo enhancement of platelet activating factor-induced prostacyclin production by OKY-046, a selective inhibitor of thromboxane A2 synthase.
Davenport, NJ; Feuerstein, GZ; Goldstein, RE, 1991
)
0.28
"35 mg/animal) significantly reduced the airway responses produced by inhalation of leukotriene C4 and STA2, in a dose-dependent manner, while the pretreatment did not affect the histamine dose-response curve."( Inhibitory effect of inhalation of a thromboxane synthetase inhibitor on bronchoconstriction induced by aerosolized leukotriene C4 and thromboxane A2 analogue in anesthetized guinea pigs.
Fujimura, M; Matsuda, T; Miyake, Y; Ogawa, H; Saito, M; Sakamoto, S, 1991
)
0.28
" In this study, we quantitated the dose-response effects of topically applied PAF on microvascular permselectivity and investigated the biochemical pathways of this compound."( Effect of platelet-activating factor on microvascular permselectivity: dose-response relations and pathways of action in the hamster cheek pouch microcirculation.
Dillon, PK; Durán, WN, 1988
)
0.27
"0 micrograms/ml of leukotriene C4, while the pretreatment did not affect the histamine dose-response curve."( Secondary release of thromboxane A2 in aerosol leukotriene C4-induced bronchoconstriction in guinea pigs.
Fujimura, M; Kanamori, K; Matsuda, T; Miyake, Y; Uotani, K, 1988
)
0.27
" Airway responsiveness was assessed with dose-response curves of acetylcholine aerosol versus total pulmonary resistance before and 6 and 24 h after inhalation with ragweed antigen."( Inhibition of antigen-induced airway hyperresponsiveness by a thromboxane synthetase inhibitor (OKY-046) in allergic dogs.
Aizawa, H; Becker, AB; Chung, KF; Frick, O; Gold, WM; Nadel, JA, 1986
)
0.27
"2 micrograms/ml), indicating that OPS may be a useful dosage form rather than injection."( Rectal absorption of ozagrel from suppositories in rabbits.
Adachi, I; Horikoshi, I; Kanamoto, I; Zheng, NX, 1994
)
0.61
" Metabolites M1 and M2 appeared in plasma immediately after intravenous (iv) dosing of the parent drug."( Pharmacokinetics of ozagrel and its metabolites after intravenous and oral administrations.
Hara, Y; Iwaki, M; Ogiso, T; Tanino, T, 1997
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cinnamic acidsAny alpha,beta-unsaturated monocarboxylic acid based on the cinnamic acid skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cystic fibrosis transmembrane conductance regulatorHomo sapiens (human)IC50 (µMol)3.43000.140016.625050.0000AID1224863
Thromboxane A2 receptor Homo sapiens (human)IC50 (µMol)100.00000.00110.71065.2000AID212275
Thromboxane-A synthase Homo sapiens (human)IC50 (µMol)0.08640.00091.230410.0000AID210476; AID210477; AID212615; AID212629; AID212971
Thromboxane-A synthaseRattus norvegicus (Norway rat)IC50 (µMol)0.20000.00400.39231.5000AID210483
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
smooth muscle contractionThromboxane A2 receptor Homo sapiens (human)
G protein-coupled receptor signaling pathwayThromboxane A2 receptor Homo sapiens (human)
response to nutrientThromboxane A2 receptor Homo sapiens (human)
response to xenobiotic stimulusThromboxane A2 receptor Homo sapiens (human)
positive regulation of blood coagulationThromboxane A2 receptor Homo sapiens (human)
response to testosteroneThromboxane A2 receptor Homo sapiens (human)
thromboxane A2 signaling pathwayThromboxane A2 receptor Homo sapiens (human)
response to ethanolThromboxane A2 receptor Homo sapiens (human)
positive regulation of angiogenesisThromboxane A2 receptor Homo sapiens (human)
positive regulation of smooth muscle contractionThromboxane A2 receptor Homo sapiens (human)
cellular response to lipopolysaccharideThromboxane A2 receptor Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisThromboxane A2 receptor Homo sapiens (human)
inflammatory responseThromboxane A2 receptor Homo sapiens (human)
positive regulation of blood pressureThromboxane A2 receptor Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane A2 receptor Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationThromboxane A2 receptor Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayThromboxane A2 receptor Homo sapiens (human)
prostaglandin biosynthetic processThromboxane-A synthase Homo sapiens (human)
icosanoid metabolic processThromboxane-A synthase Homo sapiens (human)
cyclooxygenase pathwayThromboxane-A synthase Homo sapiens (human)
intracellular chloride ion homeostasisThromboxane-A synthase Homo sapiens (human)
response to ethanolThromboxane-A synthase Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane-A synthase Homo sapiens (human)
response to fatty acidThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
thromboxane A2 receptor activityThromboxane A2 receptor Homo sapiens (human)
guanyl-nucleotide exchange factor activityThromboxane A2 receptor Homo sapiens (human)
protein bindingThromboxane A2 receptor Homo sapiens (human)
monooxygenase activityThromboxane-A synthase Homo sapiens (human)
thromboxane-A synthase activityThromboxane-A synthase Homo sapiens (human)
iron ion bindingThromboxane-A synthase Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygenThromboxane-A synthase Homo sapiens (human)
heme bindingThromboxane-A synthase Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityThromboxane-A synthase Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
acrosomal vesicleThromboxane A2 receptor Homo sapiens (human)
plasma membraneThromboxane A2 receptor Homo sapiens (human)
nuclear speckThromboxane A2 receptor Homo sapiens (human)
plasma membraneThromboxane A2 receptor Homo sapiens (human)
endoplasmic reticulumThromboxane-A synthase Homo sapiens (human)
endoplasmic reticulum membraneThromboxane-A synthase Homo sapiens (human)
cytosolThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (64)

Assay IDTitleYearJournalArticle
AID210482Tested ex vivo against TXA2 production in rat serum at 1 hr after peroral dose of 30 mg/kg and anesthetized with ether1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID197384Increase in serum prostaglandin I2 levels in incubated whole blood from rats, 1 hr following 1 mg/kg p.o.1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives.
AID91182Inhibitory activity of the compound against leukotriene (LT) B4 production in human neutrophils1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
AID626510Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition rate of ADP-induced platelet aggregation at 200 uM after 5 mins by aggregometry2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.
AID186291Tested ex vivo against serum TXB2 production at 1 hr after oral dose of 3 mg/kg of drug to rat1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID160938In vitro inhibition of platelet activating factor induced platelet aggregation in rabbit platelet rich plasma (PRP); NT means not tested2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs.
AID197381Enhancement of prostaglandin E2 levels in serum of incubated whole blood at 1 hr after an oral dose of 1 mg/kg1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives.
AID183565Inhibition of thromboxane B2 production in whole blood of rats 1 hr following 1 mg/kg p.o.1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives.
AID212617Inhibition of thromboxane A2 synthetase as reduced ADP-induced aggregation of human platelet rich plasma in the presence of pig aortal microsomes1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
[(1H-imidazol-1-yl)methyl]- and [(3-pyridinyl)methyl]pyrroles as thromboxane synthetase inhibitors.
AID165600The compound was tested for inhibition of Platelet activating factor (PAF) induced platelet aggregation in rabbit platelet rich plasma; Not tested2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
AID160940Tested in vitro for the inhibition of Platelet activating factor (PAF) induced platelet aggregation in rabbit platelet rich plasma (PRP); NT=Not tested2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
AID183570Inhibition of thromboxane B2 production in whole blood of rats, 6 hr after a peroral dose of 1.0 mg/kg1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives.
AID92868Inhibitory activity of the compound against Thromboxane TXB2 production in human blood platelets1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
AID92980In vitro inhibition of Thromboxane A2 synthesis in human platelet1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities.
AID212781Relative potency of thromboxane A2 synthetase as reduced ADP-induced aggregation of human platelet rich plasma compared to dazoxiben1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
[(1H-imidazol-1-yl)methyl]- and [(3-pyridinyl)methyl]pyrroles as thromboxane synthetase inhibitors.
AID1732639Inhibition of human CYP4Z1 overexpressed in human MCF7 cells at 1 uM using luciferin-3FBE as substrate incubated for 24 hrs followed by substrate addition by luminescence based assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor.
AID1452923Inhibition of TXS in human platelet rich plasma assessed as decrease in TXB2 production at 100 uM using arachidonic acid after 5 mins by ELISA2017European journal of medicinal chemistry, Jul-28, Volume: 135Synthesis and mechanistic evaluation of novel N'-benzylidene-carbohydrazide-1H-pyrazolo[3,4-b]pyridine derivatives as non-anionic antiplatelet agents.
AID210476Tested in vitro against TXA2 synthetase inhibitory activity in human microsome1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID210483Tested in vitro against TXA2 synthetase inhibitory activity in rat platelet1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID626459Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition rate of ADP-induced platelet aggregation at 400 uM after 5 mins by aggregometry2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.
AID186292Tested ex vivo against serum TXB2 production at 1 hr after oral dose of 30 mg/kg of drug to rat1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID212971In vitro inhibition of thromboxane synthase (TXA2) in human platelet microsomes [reduced formation of TXB2 from prostaglandin H2(PGH2)]2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
AID1732638Inhibition of human CYP4Z1 expressed in permeabilized fission AZ3 yeast cells at 100 nM using luciferin-3FBE as substrate incubated for 3 hrs by luminescence based enzyme bag assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor.
AID210478Tested in vitro against TXA2 synthetase inhibitory activity in human whole blood1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID73835In vitro bronchodilatory activity in guinea pig isolated tracheal strips1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID178240Inhibition of serum TXB2 production in the rats after intravenous administration2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
AID1713539Inhibition of diphenolase activity of mushroom tyrosinase using L-DOPA substrate2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
ArgTX-636, a polyamine isolated from spider venom: A novel class of melanogenesis inhibitors.
AID212107Tested for inhibition of thromboxane A2 (TXA2) production in rat serum by ex vivo assay after peroral dose of 30 mg/kg1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones.
AID132331Ability to protect mice from the lethal effect of Platelet activating factor on iv administration of compound; not tested2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
AID183555Inhibition of thromboxane B2 production in whole blood of rat 45 min after intravenous injection of compound at 0.1 mg/kg1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives.
AID210484Tested in vitro against TXA2 synthetase inhibitory activity in rat whole blood1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID178241Inhibition of serum TXB2 production in the rats after peroral administration2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
AID212106Tested for inhibition of thromboxane A2 (TXA2) production in rabbit by in vitro assay at 1 uM1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones.
AID183563Inhibition of thromboxane B2 production in whole blood of rat 75 min after intravenous injection of compound at 0.1 mg/kg1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives.
AID626513Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation after 5 mins by aggregometry2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.
AID1871836Antiplatelet aggregation activity in rabbit platelet assessed as reduction in ADP-induced platelet aggregation2022European journal of medicinal chemistry, Jan-15, Volume: 228Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
AID212615In vitro inhibition of TXB2 production by incubating prostaglandin H2 with human platelet microsomes.2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs.
AID92869Inhibitory activity of the compound against Thromboxane TXB2 production in human whole blood1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
AID212629Thromboxane A2 synthase inhibitory activity was measured from inhibition of thromboxane B2 production in human platelet microsomes2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID626512Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition rate of ADP-induced platelet aggregation at 50 uM after 5 mins by aggregometry2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.
AID128158Ability to protect mice from the lethal effect of Platelet activating factor on po administration of compound; not tested2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID212979Thromboxane synthase inhibitor (TxSI) activity was assessed by ex vivo inhibition of serum TXB2 production in rat after oral administration2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
AID114743Tested in vivo for Platelet activating factor (PAF) antagonist in mice after Intravenous administration using PAF-induced death assay; NT = not tested2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
AID626511Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition rate of ADP-induced platelet aggregation at 100 uM after 5 mins by aggregometry2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.
AID179761In vitro inhibition of thromboxane A2 production in rat platelet-rich plasma.1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives.
AID183551Inhibition of thromboxane B2 production in whole blood of rat 15 min after intravenous injection of compound at 0.1 mg/kg1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives.
AID92870Inhibitory activity of the compound against leukotriene (LT) B4 production in human whole blood1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
AID113512In vivo for Platelet activating factor (PAF) antagonistic activity in mice after oral administration using PAF-induced death assay; NT = not tested2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
AID78347In vivo inhibitory effect on airway constriction induced by histamine 2-5 micro g/kg iv at 1 min after 10 mg/kg iv dose of compound1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID183566Inhibition of thromboxane B2 production in whole blood of rats, 3h after a peroral dose of 1.0 mg/kg1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives.
AID212275In vitro thromboxane-A2 receptor binding affinity to displace by 50% [3H]-SQ 29548 binding from washed human platelets1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
AID212976Thromboxane synthase inhibitor (TxSI) activity assessed by ex vivo inhibition of serum TXB2 production in rat after Intravenous administration2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
AID210479Tested in vitro against rabbit thromboxane A2 synthetase (TXA2) at 1 uM1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID78346In vivo inhibitory effect on airway constriction induced by histamine 2-5 micro g/kg iv at 1 min after 10 mg/kg intravenous dose in anesthetized guinea pigs1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones.
AID73834Tested in vitro for bronchodilatory activity by spontaneous tone inhibition in guinea pig tracheal strips1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones.
AID212100In vitro inhibition of thromboxane-A2 synthase in rat whole blood during clotting at 37 degrees Centigrade1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
AID210477Tested in vitro against TXA2 synthetase inhibitory activity in human platelet1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID1452917Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method relative to control2017European journal of medicinal chemistry, Jul-28, Volume: 135Synthesis and mechanistic evaluation of novel N'-benzylidene-carbohydrazide-1H-pyrazolo[3,4-b]pyridine derivatives as non-anionic antiplatelet agents.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345256Human CYP5A1 (Prostaglandin synthases)1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (499)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990153 (30.66)18.7374
1990's231 (46.29)18.2507
2000's72 (14.43)29.6817
2010's37 (7.41)24.3611
2020's6 (1.20)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.50 (24.57)
Research Supply Index6.33 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index40.35 (26.88)
Search Engine Supply Index1.92 (0.95)

This Compound (30.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials31 (5.86%)5.53%
Reviews21 (3.97%)6.00%
Case Studies13 (2.46%)4.05%
Observational1 (0.19%)0.25%
Other463 (87.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Edaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke [NCT00200356]Phase 4401 participants (Actual)Interventional2004-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00200356 (10) [back to overview]Barthel Index Score
NCT00200356 (10) [back to overview]Baseline NIH Stroke Scale Score
NCT00200356 (10) [back to overview]Japan Stroke Scale (Motor Function) Score at 1 Month
NCT00200356 (10) [back to overview]Japan Stroke Scale (Motor Function) Score at 14 Days
NCT00200356 (10) [back to overview]Japan Stroke Scale (Motor Function) Score at 3 Months
NCT00200356 (10) [back to overview]Modified Rankin Scale Score
NCT00200356 (10) [back to overview]NIH Stroke Scale Score at 1 Month
NCT00200356 (10) [back to overview]NIH Stroke Scale Score at 14 Days
NCT00200356 (10) [back to overview]NIH Stroke Scale Score at 3 Months
NCT00200356 (10) [back to overview]the Rate of Patients With a Modified Rankin Scale Score of 0-1

Barthel Index Score

"The Barthel Index of Activities of Daily Living measures functional disability by quantifying patient performance in 10 activities of daily life. These activities can be grouped according to self-care (feeding, grooming, bathing, dressing, bowel and bladder care, and toilet use) and mobility (ambulation, transfers, and stair climbing). 5-point increments are used in scoring, with a maximal score of 100 indicating that a patient is fully independent in physical functioning, and a lowest score of 0 representing a totally dependent bed-ridden state.~The number of patients with 95-100 Barthel Index was evaluated at at 3 months after treatment initiation." (NCT00200356)
Timeframe: 3 months

Interventionparticipants (Number)
Edaravone148
Ozagrel133

[back to top]

Baseline NIH Stroke Scale Score

The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). (NCT00200356)
Timeframe: Before treatment initiation

Interventionscores on a scale (Mean)
Edaravone3.7
Ozagrel3.8

[back to top]

Japan Stroke Scale (Motor Function) Score at 1 Month

The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 1 month after treatment initiation. (NCT00200356)
Timeframe: 1 month

Interventionunits on a scale (Mean)
Edaravone3.632
Ozagrel3.680

[back to top]

Japan Stroke Scale (Motor Function) Score at 14 Days

The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 14 days after treatment initiation. (NCT00200356)
Timeframe: 14 days

Interventionunits on a scale (Mean)
Edaravone4.521
Ozagrel4.686

[back to top]

Japan Stroke Scale (Motor Function) Score at 3 Months

The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 3 months after treatment initiation. (NCT00200356)
Timeframe: 3 months

Interventionunits on a scale (Mean)
Edaravone2.507
Ozagrel2.927

[back to top]

Modified Rankin Scale Score

The number of patients with an Modified Rankin Scale score of 0-1 was evaluated at 6 months after treatment initiation. The Modified Rankin Scale has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability. (NCT00200356)
Timeframe: 6 months

Interventionparticipants (Number)
Edaravone112
Ozagrel108

[back to top]

NIH Stroke Scale Score at 1 Month

The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 1 month after treatment initiation. (NCT00200356)
Timeframe: 1 month

Interventionparticipants (Number)
Edaravone117
Ozagrel119

[back to top]

NIH Stroke Scale Score at 14 Days

The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 14 days after treatment initiation. (NCT00200356)
Timeframe: 14 days

Interventionparticipants (Number)
Edaravone98
Ozagrel108

[back to top]

NIH Stroke Scale Score at 3 Months

The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 3 months after treatment initiation. (NCT00200356)
Timeframe: 3 months

Interventionparticipants (Number)
Edaravone135
Ozagrel140

[back to top]

the Rate of Patients With a Modified Rankin Scale Score of 0-1

The number of patients with mRS score of 0-1 (good outcome) at 3 months after treatment initiation. The mRS has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability. (NCT00200356)
Timeframe: 3 months

,
Interventionparticipants (Number)
Score(0-1)012345Death
Edaravone109466337221922
Ozagrel98395940292431

[back to top]